hapabapa
UBS has upgraded Roche (OTCQX:RHHBY
“We see sustained outperformance of Vabysmo and Ocrevus as key drivers of near-term growth, with additional benefit from Xolair food allergy and potential upside from Elevidys ex-US,” UBS
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801706/image_2175801706.jpg?io=getty-c-w750
2025-02-13 17:52:47
